N
Neville Davidson
Researcher at Broomfield Hospital
Publications - 37
Citations - 13353
Neville Davidson is an academic researcher from Broomfield Hospital. The author has contributed to research in topics: Breast cancer & Metastatic breast cancer. The author has an hindex of 23, co-authored 37 publications receiving 12171 citations. Previous affiliations of Neville Davidson include The Royal Marsden NHS Foundation Trust & National Health Service.
Papers
More filters
Journal ArticleDOI
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert,Luc Thomas,Igor Bondarenko,Steven J. O'Day,Jeffrey S. Weber,Claus Garbe,Céleste Lebbé,Jean Francois Baurain,Alessandro Testori,Jean-Jacques Grob,Neville Davidson,Jon M. Richards,Michele Maio,Axel Hauschild,Wilson H. Miller,Pere Gascón,Michal Lotem,Kaan Harmankaya,Ramy Ibrahim,Stephen Francis,Tai-Tsang Chen,R. Humphrey,Axel Hoos,Jedd D. Wolchok +23 more
TL;DR: Ipilimumab (at a dose of 10 mg per kilogram) in combination with dacarbazine, as compared with dACarbazine plus placebo, improved overall survival in patients with previously untreated metastatic melanoma.
Journal ArticleDOI
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Charles E. Geyer,John K. Forster,Deborah Lindquist,Stephen Chan,C. Gilles Romieu,Tadeusz Pienkowski,Agnieszka Jagiełło-Gruszfeld,John Crown,Arlene Chan,Bella Kaufman,Dimosthenis Skarlos,Mario Campone,Neville Davidson,Mark S. Berger,Cristina Oliva,Stephen D. Rubin,S. Stein,David Cameron +17 more
TL;DR: Lapatinib plus capecitabine is superior to cape citabine alone in women with HER2-positive advanced breast cancer that has progressed after treatment with regimens that included an anthracycline, a taxane, and trastuzumab.
Journal ArticleDOI
Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer
William J. Gradishar,Sergei Tjulandin,Neville Davidson,Heather S. Shaw,Neil Desai,P. Bhar,Michael M. Hawkins,Joyce O'Shaughnessy +7 more
TL;DR: The improved therapeutic index and elimination of corticosteroid premedication required for solvent-based taxanes make the novel albumin-bound paclitaxel ABI-007 an important advance in the treatment of MBC.
Journal ArticleDOI
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
David Cameron,Michelle Casey,Michael F. Press,Deborah Lindquist,Tadeusz Pienkowski,C. Gilles Romieu,Stephen Chan,Agnieszka Jagiełło-Gruszfeld,Bella Kaufman,John Crown,Arlene Chan,Mario Campone,Patrice Viens,Neville Davidson,Veira Gorbounova,Johannes Isaac Raats,Dimosthenis Skarlos,B. Newstat,Debasish F. Roychowdhury,Paolo Paoletti,Cristina Oliva,Stephen D. Rubin,S. Stein,Charles E. Geyer +23 more
TL;DR: The addition of lapatinib to capecitabine provides superior efficacy for women with HER2-positive, advanced breast cancer progressing after treatment with anthracycline-, taxane-, and trastuzumab-based therapy.
Journal ArticleDOI
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials
Joop P. W. van den Bergh,Kathleen I. Pritchard,KS Albain,Stewart J. Anderson,Rodrigo Arriagada,William E. Barlow,W. Bergsten-Nordström,Judith M Bliss,Francesco Boccardo,Rosie Bradley,Marc Buyse,David Cameron,Mike Clarke,M. Coates,Robert E. Coleman,C Correa,J. Costantino,Jack Cuzick,Neville Davidson,C Davies,A. Di Leo,Mitchell Dowsett,Marianne Ewertz,John F. Forbes,R. D. Gelber,R. Geyer,R. Gianni,M. Gnant,A. Goldhirsch,Richard Gray,Daniel F. Hayes,C. Hill,JN Ingle,Wolfgang Janni,Elizabeth MacKinnon,M. Martin,Paul McGale,Larry Norton,Yasuo Ohashi,Soonmyung Paik,Hongchao Pan,E. A. Perez,Richard Peto,R. Piccart,Lori J. Pierce,Vinod Raina,Peter M. Ravdin,J.F.R. Robertson,E.J.T. Rutgers,Joseph A. Sparano,Sandra M. Swain,Carolyn W. Taylor,Giuseppe Viale,G. von Minckwitz,Xiang Wang,Timothy J. Whelan,Nicholas Wilcken,Eric P. Winer,Norman Wolmark,William C. Wood +59 more
TL;DR: In this paper, the authors conducted a collaborative meta-analysis to clarify the risks and benefits of adjuvant bisphosphonate treatment in early breast cancer, and found that the reduction in bone recurrence was more definite (0.73-0.94; 2p=0.004).